Reference number |
2025-00223 |
Coordinator |
Axial Cell Systems AB |
Funding from Vinnova |
SEK 15 000 |
Project duration |
February 2025 - March 2025
|
Status |
Completed |
Venture |
Global cooperation 2025 |
Important results from the project
Participation in Swiss Nordic Bio provided valuable insights even though the high-level objective was only partially achieved. The matchmaking service did not meet expectations, especially regarding investor activity. However, the meetings generated insights that are implemented in our strategy. Subsequent contacts have led to new meetings in Stockholm. The project has strengthened our position in the life science network and contributed insights for our development in gene therapy for ALS.
Expected long term effects
Opportunity to raise capital. Opportunity to license our gene therapies.
Approach and implementation
The project focused on participation in Swiss Nordic Bio for networking with investors and pharmaceutical companies. The activities were appropriate and developed according to plan, although the results from the matchmaking service fell short of expectations. The schedule was followed without deviations. When it became clear that the number of meetings via the official service would be limited, I arranged supplementary meetings with my own contacts in Zurich to maximize the value of the trip.
The project description has been provided by the project members themselves and the text has not been looked at by our editors.